Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlkermesFRA:8AK +1.25%66 EV-to-FCF is 45.76 as of Jul. 20, 2026, which is 311% above its 10-year median of 11.13. GuruFocus rates FRA:8AK with a GF Score™ of 66/100 and a GF Value™ of €23.53 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 565 Drug Manufacturers companies, Alkermes ranks worse than 71.15% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alkermes's Enterprise Value is €8,656 Mil.
Alkermes's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €189 Mil. Therefore, Alkermes's EV-to-FCF for today is 45.76.
The historical rank and industry rank for Alkermes's EV-to-FCF or its related term are showing as below:
FRA:8AK'
s EV-to-FCF Range Over the Past 10 Years
Min: -1177.44 Med: 11.13 Max: 1246.35
Current: 44.44
During the past 13 years, the highest EV-to-FCF of Alkermes was 1246.35. The lowest was -1177.44. And the median was 11.13.
FRA:8AK's EV-to-FCF is ranked worse than 71.15% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs FRA:8AK: 44.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alkermes's share price for today is €45.50.
Alkermes's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alkermes EV-to-FCF Related Terms
Alkermes EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Alkermes's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkermes EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkermes's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alkermes's EV-to-FCF falls into.
Alkermes's current Enterprise Value is €8,656 Mil.
Alkermes's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €189 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes (FRA:8AK) has a EV-to-FCF of 45.76 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alkermes and its competitors. This is 311% above median its historical median of 11.13. According to the industry distribution chart, Alkermes ranks #402 out of 565 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Alkermes' EV-to-FCF too high?
Alkermes' current EV-to-FCF of 45.76 is 311% above median its 10-year median of 11.13. The Drug Manufacturers industry median EV-to-FCF is 20.96. Alkermes' value of 45.76 is 118.3% above this industry median. Based on the distribution chart, Alkermes ranks #402 out of 565 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alkermes has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' EV-to-FCF compare to HIMS and LNTH?
According to the Drug Manufacturers industry distribution chart, Alkermes ranks #402 out of 565 companies for EV-to-FCF. This places Alkermes in the lower half of its industry. The industry median EV-to-FCF is 20.96. Alkermes' value of 45.76 is 118.3% above this benchmark. While the company's 10-year median is 11.13 vs. the industry median of 20.96, Alkermes has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkermes's current EV-to-FCF of 45.76 is 118.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alkermes and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkermes's current EV-to-FCF is 45.76, which is 311% above median its own 10-year median of 11.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (FRA:8AK) is currently considered Significantly Overvalued. The stock's GF Value™ is €23.53, compared to a current price of €45.50 — trading 93.4% above its estimated fair value. The current EV-to-FCF is 45.76, which is 311% above median its 10-year median of 11.13 and 118.3% above the Drug Manufacturers industry median of 20.96. Alkermes' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Alkermes (FRA:8AK), the current EV-to-FCF is 45.76 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkermes (FRA:8AK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkermes stock appears to be overvalued.
The current stock price of €45.50 is trading 93.4% above its estimated GF Value™ of €23.53.
GuruFocus considers Alkermes to be Significantly Overvalued.
Key valuation signals for FRA:8AK:
EV-to-FCF: 45.76 (311% above median its 10-year median of 11.13)
GF Value™: €23.53 vs. price of €45.50 (93.4% above fair value)
Industry Position: 118.3% above the Drug Manufacturers median (#402 of 565)
No single metric tells the full story. See the FRA:8AK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
66GF Score
Get the complete analysis for FRA:8AK
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AK has been successfully added to your 
